Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2006

01-05-2006

Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy

Authors: Paul H. Sugarbaker, MD, FACS, FRCS, Robert Alderman, PA-C, Gary Edwards, PA-C, Christina Ellen Marquardt, RN, Vadim Gushchin, MD, Jesus Esquivel, MD, David Chang, MS

Published in: Annals of Surgical Oncology | Issue 5/2006

Login to get access

Abstract

Background

Appendiceal mucinous neoplasms present, in most patients, with peritoneal dissemination at the time of initial diagnosis. Patients may have a borderline tumor showing disseminated peritoneal adenomucinosis or an aggressive malignancy identified as peritoneal mucinous adenocarcinoma. Patients with these diagnoses were treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.

Methods

A database was established in 1998 that prospectively evaluated the morbidity and mortality of this group of patients. By using common toxicity grading criteria, 8 categories were scored on a grade of I to V. Grade IV indicated that the adverse event required urgent and definitive intervention: often a return to the operating room or to the surgical intensive care unit. Grade V indicated that the adverse events resulted in the patient’s death. Adverse events were tabulated for each cytoreduction performed in these appendiceal malignancy patients.

Results

There were 356 procedures in patients taken to the operating room who received cytoreductive surgery with peritonectomy procedures plus heated intraoperative intraperitoneal chemotherapy. Only patients who had this combined treatment at our institution were included in the analysis. The total 30-day or in-hospital mortality was 2.0%. Nineteen percent of procedures were accompanied by at least one grade IV adverse event, and 11.1% of patients returned to the operating room. The most common category of grade IV complications was hematological (28%), followed by gastrointestinal (26%).

Conclusions

The mortality of 2.0% and the overall grade IV morbidity of 19% in these patients may be acceptable in light of modern standards for the management of gastrointestinal cancer.
Literature
1.
Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg Oncol 1994;219:112–9
2.
Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms. A clinicopathological analysis of 107 cases. Am J Surg Pathol 2003;27:1089–103CrossRefPubMed
3.
Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei. An analysis of surgical therapy. Ann Surg 2005;241:300–8CrossRefPubMed
4.
Sugarbaker PH. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–31.CrossRefPubMed
5.
Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003;138:26–33PubMed
6.
Van Ruth S, Acherman YIZ, van de Vijver MJ, Hart AAM, Verwaal VJ, Zoetmulder FAN. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol 2003;29:682–8PubMed
7.
Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004;11:393–8CrossRefPubMed
8.
Güner Z, Schmidt U, Dahlke MH, Schlitt HJ, Klempnauer J, Piso P. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis 2005; 20:155–60CrossRefPubMed
9.
Loungnarath R, Causeret S, Bossard N, et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 2005; 48:1372–9CrossRefPubMed
10.
11.
De Lima Vazquez V, Sugarbaker PH. Cholecystectomy, lesser omentectomy and stripping of the omental bursa, a peritonectomy procedure. J Surg Onco 2003;84:45–9
12.
De Lima Vazquez V, Sugarbaker PH. Total anterior parietal peritonectomy. J Surg Oncol 2003;83:261–3
13.
Sugarbaker PH. Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Br J Surg 2002;89:202–12
14.
Sugarbaker PH. Management of Peritoneal Surface Malignancy Using Intraperitoneal Chemotherapy and Cytoreductive Surgery. A Manual for Physicians and Nurses. 3rd ed. Grand Rapids, MI: Ludann Co, 1998
15.
Sugarbaker PH, Averbach AM, Jacquet P, Stephens AD, Stuart OA. A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. In: Sugarbaker PH, ed. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer, 1996: 415–21
16.
Yan H, Pestieau SR, Shmookler BM, Sugarbaker PH. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure vs. success with a second-look operation. Mod Pathol 2001;14:164–71CrossRefPubMed
17.
Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, relationship to mucinous borderline (low malignant potential) tumors of the ovary. In: Fechner RE, Rosen PP, eds. Anatomic Pathology. Chicago: ASCP Press, 1997:197–226
18.
Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43(Suppl):S15–25PubMed
19.
Schnake KJ, Sugarbaker PH, Yoo D. Neutropenia following perioperative intraperitoneal chemotherapy. Tumori 1999;85:41–6PubMed
20.
Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma of colonic origin. Natural history and presentation of a curative approach to treatment. Dis Colon Rectum 1987;30:772–9PubMed
21.
Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–32PubMed
22.
Murio JE, Sugarbaker PH. Gastrointestinal fistula following cytoreductive procedures for peritoneal carcinomatosis: incidence and outcome. J Exp Clin Cancer Res 1993;3:153–8
23.
Fernandez-Trigo V, Sugarbaker PH. Diagnosis and management of postoperative gastrointestinal fistulas: a kinetic analysis. J Exp Clin Cancer Res 1994;13:233–41
24.
Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113:631–6PubMed
25.
Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996;77:2622–9CrossRefPubMed
26.
Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the Coliseum technique. Ann Surg Oncol1999;6:790–6CrossRefPubMed
27.
Sugarbaker PH, Welch L, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003;12:605–21
28.
Elias D, Blot F, Et Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71–6CrossRefPubMed
29.
Butterworth SA, Panton ONM, Klaassen DJ, Shah AM, McGregor GI. Morbidity and mortality associated with intraperitoneal chemotherapy for pseudomyxoma peritonei. Am J Surg 2002;183:529–32CrossRefPubMed
30.
Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10:863–9CrossRefPubMed
31.
Pilati P, Mocellin S, Rossi CR, et al. Cytoreductive surgery combined with hyperthermic intraoperative intraperitoneal chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003;10:508–13CrossRefPubMed
32.
Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004;11:178–86PubMed
33.
Ahmad SA, Kim J, Sussman JJ, et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 2004;11:387–92PubMed
34.
Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FAN. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004;85:61–7CrossRefPubMed
35.
Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005; 31:53–8CrossRefPubMed
36.
Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion. Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006; 106:1144–53CrossRefPubMed
Metadata
Title
Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy
Authors
Paul H. Sugarbaker, MD, FACS, FRCS
Robert Alderman, PA-C
Gary Edwards, PA-C
Christina Ellen Marquardt, RN
Vadim Gushchin, MD
Jesus Esquivel, MD
David Chang, MS
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.03.079

Other articles of this Issue 5/2006

Annals of Surgical Oncology 5/2006 Go to the issue

OriginalPaper

Comparison of Surgical Results of D2 Versus D3 Gastrectomy (Para-Aortic Lymph Node Dissection) for Advanced Gastric Carcinoma: A Multi-Institutional Study

Editorial

Carcinoembryonic Antigen, Biomarker Discovery, and Trial Design

OriginalPaper

Management of Well-Differentiated Thyroglossal Remnant Thyroid Carcinoma: Time To Close the Debate? Report of Five New Cases and Proposal of a Definitive Algorithm for Treatment

Editorial

The “Alphabet Soup” of Peritoneal Dissemination From Appendiceal Neoplasms and Other Malignancies

OriginalPaper

Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease

OriginalPaper

18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Scanning Affects Surgical Management in Selected Patients With High-Risk, Operable Breast Carcinoma